KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) EBIAT (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBIAT for 16 consecutive years, with $50000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIAT rose 108.21% year-over-year to $50000.0, compared with a TTM value of $69000.0 through Sep 2025, up 101.74%, and an annual FY2024 reading of -$2.3 million, up 69.97% over the prior year.
  • EBIAT was $50000.0 for Q3 2025 at TherapeuticsMD, down from $551000.0 in the prior quarter.
  • Across five years, EBIAT topped out at $112.3 million in Q2 2022 and bottomed at -$49.0 million in Q1 2022.
  • Average EBIAT over 5 years is -$9.7 million, with a median of -$2.4 million recorded in 2023.
  • The sharpest move saw EBIAT soared 363.25% in 2022, then tumbled 102.15% in 2023.
  • Year by year, EBIAT stood at -$43.0 million in 2021, then rose by 22.67% to -$33.2 million in 2022, then skyrocketed by 95.36% to -$1.5 million in 2023, then soared by 107.85% to $121000.0 in 2024, then crashed by 58.68% to $50000.0 in 2025.
  • Business Quant data shows EBIAT for TXMD at $50000.0 in Q3 2025, $551000.0 in Q2 2025, and -$653000.0 in Q1 2025.